# Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain

> **NCT02793817** · PHASE3 · COMPLETED · sponsor: **Kala Pharmaceuticals, Inc.** · enrollment: 520 (actual)

## Conditions studied

- Post Surgical Ocular Inflammation and Pain

## Interventions

- **DRUG:** KPI-121 1% Ophthalmic Suspension dosed BID
- **DRUG:** Vehicle of KPI-121 Ophthalmic Suspension dosed BID

## Key facts

- **NCT ID:** NCT02793817
- **Lead sponsor:** Kala Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2017-03
- **Final completion:** 2017-03
- **Target enrollment:** 520 (ACTUAL)
- **Last updated:** 2020-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02793817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02793817, "Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02793817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*